## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.91 indicates fundamental undervaluation. Quality metrics strong (ROE 31%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($62.46)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 9)

**1. DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!**
- Source: WJBF | 20251215T120806 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) and its officers. The lawsuit alleges that DexCom made materially false and misleading statements regarding unauthorized design changes to its G6 and G7 devices, which allegedly rendered them less reliable and posed health risks to users. Investors who purchased DexCom securities between January 8, 2024, and September 17, 2025, are encouraged to join the lawsuit, with a deadline of December 26, 2025, to request to be appointed as lead plaintiff.

**2. Class Action Filing Pursued by Pomerantz LLP Against DexCom, Inc. â€“ DXCM**
- Source: WDTN.com | 20251215T120217 | Bearish | Relevance: 100%
- Pomerantz LLP has filed a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) and its officers, alleging that the company made false and misleading statements about its G6 and G7 continuous glucose monitoring systems. The lawsuit claims that DexCom implemented unauthorized design changes that made the devices less reliable and failed to disclose material health risks, leading to significant drops in stock price following FDA warnings and analyst downgrades. Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, have until December 26, 2025, to seek appointment as Lead Plaintiff.

**3. DXCM CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. Shareholders of Securities Fraud Class Action Lawsuit**
- Source: PR Newswire | 20251214T160811 | Bearish | Relevance: 100%
- Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems and overstated their reliability, posing material health risks and leading to potential regulatory scrutiny. Investors have until December 26, 2025, to seek appointment as a lead plaintiff.

**4. Levi & Korsinsky Notifies DexCom, Inc. (DXCM) Shareholders of Class Action Lawsuit and December 26, 2025 Deadline**
- Source: WWLP | 20251214T000910 | Bearish | Relevance: 100%
- Levi & Korsinsky has announced a class action lawsuit against DexCom, Inc. (DXCM) for alleged securities fraud between January 8, 2024, and September 17, 2025. The lawsuit claims DexCom made unauthorized design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing a health risk. Shareholders who suffered losses during this period have until December 26, 2025, to learn about their rights to recovery.

**5. Levi & Korsinsky Notifies DexCom, Inc. (DXCM) Shareholders of Class Action Lawsuit and December 26, 2025 Deadline**
- Source: KXAN Austin | 20251214T000819 | Bearish | Relevance: 100%
- Levi & Korsinsky has announced a class action lawsuit against DexCom, Inc. (DXCM) shareholders, seeking to recover losses for those affected by alleged securities fraud between January 8, 2024, and September 17, 2025. The lawsuit claims DexCom made unauthorized design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and potentially posing health risks, which the company allegedly downplayed. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky to learn about their rights, with a deadline of December 26, 2025.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $77 | $75 | +3% |
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 10.1% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (2 raises, avg +11%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.3B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 27.0 |
| Current P/E | 32.4 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.8% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 79th percentile. MRS_5 at 1.2% confirms short-term momentum alignment. AM_20 at 6.0% shows strong absolute momentum above own 20MA. Outperforming sector by 5.9pp, stock-specific strength. Below SMA200 (0.90x), long-term trend not supportive. MACD histogram positive (0.78), confirming momentum. RSI neutral at 60. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.62% (CS: 79) | Strong |
| RSI_14 | 59.6 | Neutral |
| MACD Histogram | 0.78 | Bullish |
| vs SMA20 | 1.060x | Above |
| vs SMA50 | 1.045x | Above |
| vs SMA200 | 0.899x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $66.96
- **Stop Loss:** $62.46 (6.7% risk)
- **Target:** $75.96 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 222
- **Position Value:** $14,865.12
- **Portfolio %:** 14.87%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*